Evidence map›Paper›PMID 30341187›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2018

TRAF2 Deficiency in B Cells Impairs CD40-Induced Isotype Switching That Can Be Rescued by Restoring NF-κB1 Activation.

Rachel A Woolaver, Xiaoguang Wang, Yonatan Dollin, Ping Xie, Jing H Wang, Zhangguo Chen

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease.Journal of cardiovascular translational research · 2021
    Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rachel A WoolaverDepartment of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045.ORCID 0000-0003-1960-2717
Xiaoguang WangDepartment of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045.
Yonatan DollinDepartment of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045.ORCID 0000-0001-8754-1800
Ping XieDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ 08854; and.
Jing H WangDepartment of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045; zhangguo.chen@ucdenver.edu jing.wang@ucdenver.edu.ORCID 0000-0003-4343-2527
Zhangguo ChenDepartment of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045; zhangguo.chen@ucdenver.edu jing.wang@ucdenver.edu.ORCID 0000-0002-2741-0080
University of Colorado Anschutz Medical Campus · USRutgers, The State University of New Jersey · US

Funding

Mechanisms promoting translocations and mature B cell lymphomasR01CA166325 · NCI · UNIVERSITY OF COLORADO DENVER · PI WANG, JING HONG · 2012 to 2016
$1.7M
Molecular mechanisms of B cell malignant transformationR01CA158402 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI XIE, PING · 2012 to 2016
$1.6M
A Novel Approach to Evaluate Genetic Variants in Primary Antibody DeficiencyR21AI133110 · NIAID · UNIVERSITY OF COLORADO DENVER · PI WANG, JING HONG · 2018 to 2019
$428k
Role of Target DNA sequences in mutation and DNA Break GenerationR21AI110777 · NIAID · UNIVERSITY OF COLORADO DENVER · PI WANG, JING HONG · 2015 to 2016
$427k
Genomic instability mediated via differential DNA repair mechanisms in B cellsR21CA184707 · NCI · UNIVERSITY OF COLORADO DENVER · PI WANG, JING HONG · 2015 to 2016
$372k
Mechanisms underlying therapy failure of immune checkpoint inhibitors and Notch1 loss-mediated immunosuppression in head and neck cancersF31DE027854 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI WOOLAVER, RACHEL A · 2018 to 2020
$100k
NCI NIH HHS R01 CA158402NCI NIH HHS R01 CA166325NCI NIH HHS R21 CA184707NIAID NIH HHS R21 AI110777NIAID NIH HHS R21 AI133110NIDCR NIH HHS F31 DE027854
6 · The paper itself

Abstract

Effective humoral immunity requires class switch recombination (CSR) catalyzed by activation-induced cytidine deaminase (AID). In response to T cell-dependent (TD) Ags, CSR can be induced by CD40 signaling in B cells. TNFR-associated factors 2 and 3 (TRAF2/TRAF3) function as adaptors of the CD40 signaling pathway. B cell-intrinsic TRAF2 or TRAF3 (B-TRAF2 or B-TRAF3) knockout mice were previously reported to have indistinguishable phenotypes in gene expression, B cell survival and development, and enlarged peripheral lymphoid organs. However, it remains unknown whether deficiency of B-TRAF2 or B-TRAF3 differentially affects TD humoral immune responses and CD40-induced CSR. In this article, we show that B-TRAF2 is essential for optimal isotype switching induced by in vivo TD Ag immunization or by engaging CD40 in vitro. Our data clarify the controversial role of B-TRAF3 and confirm its dispensability in CD40-induced CSR. Mechanistically, CD40-induced AID expression was markedly impaired by B-TRAF2, but not B-TRAF3, deficiency. Moreover, B-TRAF2 deficiency causes defective activation of the NF-κB1 complex in a CD40-autonomous manner, and restoring CD40-induced NF-κB1 activation in TRAF2-deficient B cells rescues AID expression and CSR. We conclude that TRAF2 is essential but TRAF3 is dispensable for TD humoral immunity and CD40-induced CSR. Our studies provide significant biological bases for optimizing treatment of B cell-associated immune disorders by targeting CD40 signaling.

Indexed as

AnimalsB-LymphocytesCD40 AntigensCells, CulturedGene Expression RegulationHumansImmunity, HumoralImmunoglobulin Class SwitchingMiceMice, KnockoutNF-kappa BSignal TransductionT-Lymphocytes, Helper-InducerTNF Receptor-Associated Factor 2TNF Receptor-Associated Factor 3Transcriptional ActivationCD40 AntigensNF-kappa BTNF Receptor-Associated Factor 2TNF Receptor-Associated Factor 3

Identifiers

PMID30341187
PMCPMC6246814
OpenAlexW2896565924

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.